Hiroshi Ogawa
- Oncology top 5%
- Cancer Immunotherapy and Biomarkers 6
- Lung Cancer Research Studies 5
- Cancer Research top 5%
- Cancer Genomics and Diagnostics 4
- Physiology top 5%
- Reproductive Medicine top 5%
- Ovarian cancer diagnosis and treatment 6
-
- Lung Cancer Treatments and Mutations 13
-
- RNA modifications and cancer 6
- Chromatin Remodeling and Cancer 5
-
- Myasthenia Gravis and Thymoma 4
- Co-authors
- Haruhiko SugimuraKazuya ShinmuraHiroshi NiwaMasayuki TanahashiKazuhito FunaiYusuke InoueTakafumi SudaAkikazu Kawase
- Journals
- SHILAP Revista de lepidopterología (1 paper)Cancer Research (1 paper)Scientific Reports (1 paper)
- Partner nations
- JapanUnited StatesTaiwan
In The Last Decade
Hiroshi Ogawa
68 papers receiving 1.7k citations
Peers
Comparison fields: 5 of 85
- Oncology 612
- Pathology and Forensic Medicine 385
- Cancer Research 314
- Physiology 90
- Reproductive Medicine 146
Countries citing papers authored by Hiroshi Ogawa
This map shows the geographic impact of Hiroshi Ogawa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hiroshi Ogawa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hiroshi Ogawa more than expected).
Fields of papers citing papers by Hiroshi Ogawa
This network shows the impact of papers produced by Hiroshi Ogawa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hiroshi Ogawa. The network helps show where Hiroshi Ogawa may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Hiroshi Ogawa, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 3 | |
| 2 | 2022 | 24 | |
| 3 | 2020 | 3 | |
| 4 | 2020 | 24 | |
| 5 | 2019 | 27 | |
| 6 | 2017 | 18 | |
| 7 | 2016 | 50 | |
| 8 | 2016 | 4 | |
| 9 | 2015 | 12 | |
| 10 | 2014 | 24 | |
| 11 | 2013 | 22 | |
| 12 | 2013 | 24 | |
| 13 | 2012 | 129 | |
| 14 | 2010 | 0 | |
| 15 | 2003 | 1 | |
| 16 | 2002 | 81 | |
| 17 | 2000 | 48 | |
| 18 | 1997 | 5 | |
| 19 | 1994 | 2 | |
| 20 | 1991 | 40 |
About Hiroshi Ogawa
Hiroshi Ogawa is a scholar working on Otorhinolaryngology, Oncology and Pathology and Forensic Medicine, having authored 73 papers that have together received 1.7k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (13 papers), Cancer Immunotherapy and Biomarkers (6 papers), Ovarian cancer diagnosis and treatment (6 papers), RNA modifications and cancer (6 papers), Chromatin Remodeling and Cancer (5 papers), Lung Cancer Research Studies (5 papers), Cancer Genomics and Diagnostics (4 papers) and Myasthenia Gravis and Thymoma (4 papers). The work is most often cited by research in Oncology (612 citations), Pathology and Forensic Medicine (385 citations) and Cancer Research (314 citations). Hiroshi Ogawa has collaborated with scholars based in Japan, United States and Taiwan. Frequent co-authors include Haruhiko Sugimura, Kazuya Shinmura, Hiroshi Niwa, Masayuki Tanahashi, Kazuhito Funai, Yusuke Inoue, Takafumi Suda, Akikazu Kawase, Katsuhiro Yoshimura and Tomoaki Kahyo. Their work appears in journals such as SHILAP Revista de lepidopterología, Cancer Research and Scientific Reports.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.